Latest SPI Pharma Inc. Stories

WILMINGTON, Del., Feb. 14, 2013 /PRNewswire/ -- SPI Pharma, Inc. (Wilmington, DE), a global leader in providing pharmaceutical ingredients and technologies for patient-friendly dosage forms, announces the launch of Actimask® Ibuprofen 92S, a taste-masked Ibuprofen. It joins Actimask Acetaminophen 92M in SPI's line of taste-masked actives specifically designed for making patient-friendly orally dispersible dosage forms economically in conventional equipment. Actimask Ibuprofen 92S...

WILMINGTON, Del., June 17 /PRNewswire/ -- On Friday June 11th, Chief Judge Gregory Sleet of the United States District Court for the District of Delaware issued an important pre-trial ruling in the long-running patent dispute between SPI Pharma and Roquette Freres. The court's ruling narrowly defined several key phrases contained in Roquette's patent claims, thereby dealing a significant blow to Roquette's allegations of patent infringement. Chief Judge Sleet issued his ruling after...

WILMINGTON, Del., Aug. 11 /PRNewswire/ -- SPI Pharma, Inc., a leader in oral dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) platforms, recently announced the launch of Pharmaburst(R) 500. Using proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly raise the bar in terms of performance and economics that formulators have come to expect from a quick-dissolve dosage form. Studies show that Pharmaburst(R) 500...